These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36040662)

  • 41. Reactogenicity among health care workers following a BNT162b2 or mRNA-1273 second dose after priming with a ChAdOx1 nCOV-19 vaccine.
    Baldolli A; Fournier A; Verdon R; Michon J
    Clin Microbiol Infect; 2022 Jun; 28(6):885.e1-885.e5. PubMed ID: 35182759
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Outcome after single dose of ChAdOx1 vaccine against SARS-CoV-2 infection at 16 weeks post-vaccination among healthy adults in Saudi Arabia.
    Alghamdi A; Alsanea N; Alraey M; Joseph M; Aboud M; Almangour T; Alharbi W; Alhumidan H; Alanizi A; Al-Jedai A
    Ann Saudi Med; 2022; 42(4):223-228. PubMed ID: 35933607
    [TBL] [Abstract][Full Text] [Related]  

  • 43. BNT162b2 and ChAdOx1 nCoV-19 vaccinations, incidence of SARS-CoV-2 infections and COVID-19 hospitalisations in Scotland in the Delta era.
    Shah SA; Robertson C; Rudan I; Murray JL; McCowan C; Grange Z; Buelo A; Sullivan C; Simpson CR; Ritchie LD; Sheikh A
    J Glob Health; 2022; 12():05008. PubMed ID: 35356660
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness of ChAdOx1-S COVID-19 booster vaccination against the Omicron and Delta variants in England.
    Kirsebom FCM; Andrews N; Sachdeva R; Stowe J; Ramsay M; Lopez Bernal J
    Nat Commun; 2022 Dec; 13(1):7688. PubMed ID: 36509743
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of SARS-CoV-2 infection risks after primary vaccination with BNT162b2, BBIBP-CorV, or ChAdOx1-nCOV-19 and after homologous and heterologous booster vaccinations with these vaccines and evaluation of SARS-CoV-2 reinfection profiles.
    Djorwé S; Bousfiha A; Nzoyikorera N; Nyandwi J; Kawthar B; Malki A
    Biomedicine (Taipei); 2023; 13(3):31-48. PubMed ID: 37937059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the rapidity of SARS-CoV-2 immune responses between primary and booster vaccination for COVID-19.
    Kim JY; Kwon JS; Cha HH; Lim SY; Bae S; Kim SH
    Korean J Intern Med; 2022 Nov; 37(6):1234-1240. PubMed ID: 36217813
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assessment of Heterologous and Homologous Boosting With Inactivated COVID-19 Vaccine at 3 Months Compared With Homologous Boosting of BNT162b2 at 6 Months.
    Low EV; Tok PSK; Husin M; Suah JL; Tng BH; Thevananthan T; Appannan MR; Yahaya H; Mohd Zin S; Muhamad Zin F; Sivasampu S; Peariasamy KM
    JAMA Netw Open; 2022 Aug; 5(8):e2226046. PubMed ID: 35947381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study.
    Sritipsukho P; Khawcharoenporn T; Siribumrungwong B; Damronglerd P; Suwantarat N; Satdhabudha A; Chaiyakulsil C; Sinlapamongkolkul P; Tangsathapornpong A; Bunjoungmanee P; Nanthapisal S; Tanprasertkul C; Sritipsukho N; Mingmalairak C; Apisarnthanarak A; Tantiyavarong P
    Emerg Microbes Infect; 2022 Dec; 11(1):585-592. PubMed ID: 35114893
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees.
    Alghamdi AN; Alotaibi MI; Alqahtani AS; Al Aboud D; Abdel-Moneim AS
    Front Med (Lausanne); 2021; 8():760047. PubMed ID: 34692740
    [No Abstract]   [Full Text] [Related]  

  • 50. COVID-19 vaccination in people with multiple sclerosis, real-life experience.
    Alroughani R; Al-Hashel J; Abokalawa F; AlMojel M; Farouk Ahmed S
    Clin Neurol Neurosurg; 2022 Sep; 220():107374. PubMed ID: 35961255
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of immune activation of the COVID vaccines: ChAdOx1, BNT162b2, mRNA-1273, BBIBP-CorV, and Gam-COVID-Vac from serological human samples in Hungary showed higher protection after mRNA-based immunization.
    Fodor E; Olmos Calvo I; Kuten-Pella O; Hamar E; Bukva M; Madár Á; Hornyák I; Hinsenkamp A; Hetényi R; Földes F; Brigitta Z; Jakab F; Kemenesi G; Lacza Z
    Eur Rev Med Pharmacol Sci; 2022 Jul; 26(14):5297-5306. PubMed ID: 35916830
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50.
    Xie J; Feng S; Li X; Gea-Mallorquí E; Prats-Uribe A; Prieto-Alhambra D
    Nat Commun; 2022 Mar; 13(1):1519. PubMed ID: 35314696
    [TBL] [Abstract][Full Text] [Related]  

  • 53. COVID-19 vaccine type-dependent differences in immunogenicity and inflammatory response: BNT162b2 and ChAdOx1 nCoV-19.
    Heo JY; Seo YB; Kim EJ; Lee J; Kim YR; Yoon JG; Noh JY; Cheong HJ; Kim WJ; Yoon SY; Choi JY; Lee YJ; Lee HW; Kim SS; Kim B; Song JY
    Front Immunol; 2022; 13():975363. PubMed ID: 36119092
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Specific Antibody and the T-Cell Response Elicited by BNT162b2 Boosting After Two ChAdOx1 nCoV-19 in Common Variable Immunodeficiency.
    Goda V; Kriván G; Kulcsár A; Gönczi M; Tasnády S; Matula Z; Nagy G; Bekő G; Horváth M; Uher F; Szekanecz Z; Vályi-Nagy I
    Front Immunol; 2022; 13():907125. PubMed ID: 35784359
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pneumonia Frequency and Severity in Patients With Symptomatic COVID-19: Impact of mRNA and Adenovirus Vector Vaccines.
    Vicini S; Bellini D; Iannarelli A; Rengo M; Pelle G; Ruggiero S; Fusco M; Ambrogi C; Carbone I
    AJR Am J Roentgenol; 2022 Nov; 219(5):752-761. PubMed ID: 35642761
    [No Abstract]   [Full Text] [Related]  

  • 56. Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales.
    Kerr S; Bedston S; Bradley DT; Joy M; Lowthian E; Mulholland RM; Akbari A; Hobbs FDR; Katikireddi SV; de Lusignan S; Rudan I; Torabi F; Tsang RSM; Lyons RA; Robertson C; Sheikh A
    Int J Epidemiol; 2023 Feb; 52(1):22-31. PubMed ID: 36272418
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain.
    Burn E; Roel E; Pistillo A; Fernández-Bertolín S; Aragón M; Raventós B; Reyes C; Verhamme K; Rijnbeek P; Li X; Strauss VY; Prieto-Alhambra D; Duarte-Salles T
    Nat Commun; 2022 Nov; 13(1):7169. PubMed ID: 36418321
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
    Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
    BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses.
    Lawrenz J; Xie Q; Zech F; Weil T; Seidel A; Krnavek D; van der Hoek L; Münch J; Müller JA; Kirchhoff F
    Clin Infect Dis; 2022 Aug; 75(1):e653-e661. PubMed ID: 35079775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk factors for SARS-CoV-2 infection after primary vaccination with ChAdOx1 nCoV-19 or BNT162b2 and after booster vaccination with BNT162b2 or mRNA-1273: A population-based cohort study (COVIDENCE UK).
    Vivaldi G; Jolliffe DA; Holt H; Tydeman F; Talaei M; Davies GA; Lyons RA; Griffiths CJ; Kee F; Sheikh A; Shaheen SO; Martineau AR
    Lancet Reg Health Eur; 2022 Nov; 22():100501. PubMed ID: 36168404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.